Prospective, Open-Label Investigation of the Pharmacokinetics of Daptomycin during Cardiopulmonary Bypass Surgery
Authors:
- 1 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2499-2505
Abstract
As methicillin-resistant Staphylococcus aureus (MRSA) becomes more prevalent, vancomycin is becoming increasingly used as a prophylaxis against surgical-site infections for cardiothoracic surgeries. However, vancomycin administration can be challenging, and the pharmacokinetics of alternative antibiotics in this setting are poorly understood. The primary objective of this investigation was to describe the pharmacokinetics of daptomycin in patients undergoing coronary artery bypass graft surgery. We enrolled 15 patients undergoing coronary artery bypass surgery requiring cardiopulmonary bypass. Each subject was administered a single open-label dose of daptomycin (8 mg/kg of body weight) for surgical prophylaxis. Fourteen daptomycin plasma samples were collected. Safety outcomes between subjects who received daptomycin and 15 control subjects who received the standard-of-care antibiotic were compared. The mean maximal concentration of daptomycin ( C max ) was 84.4 ± 27.1 μg/ml; the mean daptomycin concentration during the cardiopulmonary bypass procedure was 33.2 ± 11.4 μg/ml and was 30.9 ± 12.7 μg/ml at sternum closure. Mean daptomycin concentrations at 12, 18, 24, and 48 h were 22.7 ± 9.7, 16.2 ± 8.2, 12.0 ± 4.7, and 3.5 ± 2.3 μg/ml, respectively. Mean daptomycin concentrations were consistently above the MIC at which 90% of the tested isolates are inhibited (MIC 90 ) for S. aureus and S. epidermidis during the cardiopulmonary bypass procedure. Daptomycin was not associated with surgical-site infections or differences in adverse events compared to findings for control subjects. We found that a single dose of daptomycin at 8 mg/kg was well tolerated and achieved adequate plasma concentrations against common pathogens associated with surgical-site infections after cardiothoracic surgery. Daptomycin may be considered an alternative surgical prophylaxis antibiotic for patients undergoing cardiothoracic bypass surgery who are unable to receive vancomycin.Keywords
This publication has 46 references indexed in Scilit:
- Impact of Methicillin-ResistantStaphylococcus aureusPrevalence among S.aureusIsolates on Surgical Site Infection Risk after Coronary Artery Bypass SurgeryInfection Control & Hospital Epidemiology, 2011
- Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 yearsDiagnostic Microbiology and Infectious Disease, 2010
- Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006–2008)Diagnostic Microbiology and Infectious Disease, 2010
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Early Appropriate Parenteral Antimicrobial Treatment of Complicated Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureusSurgical Infections, 2008
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Antimicrobial Prophylaxis for Surgery: An Advisory Statement from the National Surgical Infection Prevention ProjectClinical Infectious Diseases, 2004
- Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypassThe Annals of Thoracic Surgery, 2004
- Effect of Cardiopulmonary Bypass on the Pharmacokinetics of DrugsClinical Pharmacokinetics, 1982
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976